Cyclin Dependent Kinase 46 | List of Frontiers open access articles

Original Research

Published on 07 Nov 2019

Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma

in Translational Pharmacology

Songlin Liu
Dun Yuan
Yifeng Li
Qi Qi
Bingzhong Guo
Shun Yang
Jilin Zhou
Lu Xu
Tiange Chen
Chenxing Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2019.01316

4,150 views
6 citations

Systematic Review

Published on 04 Mar 2025

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer

in Breast Cancer

Jialin Zhang
Xinyu Xu
Yeyue Zhou
Jingyang Su
Jue Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1472407

5,952 views
3 citations

Original Research

Published on 06 Nov 2025

Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database

in Pharmacology of Anti-Cancer Drugs

Mengdi Zhang
Dongqing Pu
Minmin Yu
Guangxi Shi
Jingwei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1668446

2,104 views

Mini Review

Published on 15 Apr 2020

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

in Genomic Medicine

Giulia Occhipinti
Emanuela Romagnoli
Matteo Santoni
Alessia Cimadamore
Giulia Sorgentoni
Monia Cecati
Matteo Giulietti
Nicola Battelli
Alessandro Maccioni
Nadia Storti

Frontiers in Genetics

doi 10.3389/fgene.2020.00349

6,644 views
11 citations

Original Research

Published on 03 Dec 2024

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting

in Breast Cancer

Marcin Kubeczko
Anna Polakiewicz-Gilowska
Andrea D’Amico
Olgierd Chrabański
Katarzyna Świderska
Ewa Chmielik
Sławomir Blamek
Daria Handkiewicz-Junak
Michał Jarząb

Frontiers in Oncology

doi 10.3389/fonc.2024.1454844

2,918 views
2 citations

Original Research

Published on 07 Jun 2024

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis

in Breast Cancer

Marcin Kubeczko
Anna Polakiewicz-Gilowska
Katarzyna Świderska
Aleksandra Leśniak
Marta Mianowska-Malec
Barbarba Łanoszka
Konstanty Chomik
Barbara Grandys
Natalya Lisovska
Barbara Bobek-Billewicz

Frontiers in Oncology

doi 10.3389/fonc.2024.1408664

3,721 views
2 citations

Original Research

Published on 11 Aug 2022

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models

in Cancer Molecular Targets and Therapeutics

Lei Yin
Zhenglin Yao
Yue Wang
Michelle Mazuranic

Frontiers in Oncology

doi 10.3389/fonc.2022.915862

4,337 views
1 citation

Original Research

Published on 08 Mar 2022

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

in Pharmacology of Anti-Cancer Drugs

Han Fu
Zhuo-Xun Wu
Zi-Ning Lei
Qiu-Xu Teng
Yuqi Yang
Charles R. Ashby
Yixiong Lei
Yuyin Lian
Zhe-Sheng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2022.861642

7,776 views
21 citations

Review

Published on 24 Oct 2019

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors

in Gastrointestinal and Hepatic Pharmacology

Emanuel Raschi
Fabrizio De Ponti

Frontiers in Pharmacology

doi 10.3389/fphar.2019.01235

10,545 views
40 citations

Original Research

Published on 11 Dec 2025

Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system

in Breast Cancer

Jin Zhou
Xinmiao Lin
Shue Wang
Mumu Xie
Xiao Hu
Jiaqin Cai

Frontiers in Oncology

doi 10.3389/fonc.2025.1673284

1,583 views

Original Research

Published on 26 Mar 2025

Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells

in Breast Cancer

Lynn M. Marcho
Christopher C. Coss
Menglin Xu
Jharna Datta
Jasmine M. Manouchehri
Mathew A. Cherian

Frontiers in Oncology

doi 10.3389/fonc.2025.1441896

2,816 views
1 citation

Review

Accepted on 26 Feb 2026

Therapeutic advances in HR+/HER2-advanced breast cancer after failure of CDK4/6 inhibitor therapy

in Breast Cancer

Mengqi Cui
Junjuan Xiao
Lin Ma
Yue Liang
Jing Liang

Frontiers in Oncology

Case Report

Published on 24 Jan 2024

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Yajun Liang
Liya Hu
Huanlei Wu
Tiejun Yin
Jun Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1292319

3,776 views
3 citations

Review

Published on 04 Oct 2023

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression

in Breast Cancer

Malek Horani
Hikmat Abdel-Razeq

Frontiers in Oncology

doi 10.3389/fonc.2023.1272602

4,955 views
4 citations

Mini Review

Published on 05 Jul 2023

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib

in Pharmacology of Anti-Cancer Drugs

Zhimin Zhu
Qiongni Zhu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1212986

9,026 views
17 citations

Case Report

Published on 24 Aug 2023

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation

in Breast Cancer

Jyun-Yan Jhan
Wei-En Wang
Sung-Chao Chu
Chiu-Hsuan Cheng
Chung-Hsing Chang

Frontiers in Oncology

doi 10.3389/fonc.2023.1184738

4,270 views
3 citations

Articles

Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer

Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors

Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system

Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells

Therapeutic advances in HR+/HER2-advanced breast cancer after failure of CDK4/6 inhibitor therapy

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation